MARC Record from marc_columbia

LEADER: 07653cam a22004814a 4500
001 5613004
005 20221121194104.0
008 041007s2005 mauaf b 001 0 engs
010 $a 2004023743
016 7 $a101231491$2DNLM
020 $a1405127694 (alk. paper)
024 3 $a9781405127691
024 3 $z9781405127694
029 1 $aNLM$b101231491
029 1 $aNLGGC$b268997977
035 $a(OCoLC)ocm56730004
035 $a(NNC)5613004
035 $a5613004
040 $aDNLM/DLC$cDLC$dNLM$dBWK$dOCL$dOrLoB-B
042 $apcc
050 00 $aRC642$b.T46 2005
060 00 $a2005 E-332
060 10 $aWH 325$bT355 2005
082 00 $a616.1/572$222
245 00 $aTextbook of hemophilia /$cedited by Christine A. Lee, Erik E. Berntorp, W. Keith Hoots ; with a foreword by Louis M. Aledort.
260 $aMalden, Mass. ;$aOxford :$bBlackwell Pub.,$c2005.
300 $axii, 400 pages, 4 unnumbered pages of plates :$billustrations (some color) ;$c29 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $g1.$tOverview of hemostasis /$rKenneth G. Mann and Kathleen Brummel Ziedins -- $g2.$tCellular processing of factors VIII and IX /$rRandal J. Kaufman -- $g3.$tWork-up of a bleeding adult /$rBarry White and Clodagh Ryan -- $g4.$tMolecular basis of hemophilia A /$rGeoffrey Kemball-Cook and Edward Tuddenham -- $g5.$tHemophilia A : role of factor VIII in coagulation /$rEvgueni L. Saenko and Natalya M. Ananyeva -- $g6.$tNatural history of inhibitor development in children with severe hemophilia A treated with factor VIII products /$rJeanne M. Lusher -- $g7.$tProphylaxis /$rH. Marijke van den Berg and Kathelijn Fischer -- $g8.$tContinuous infusion of coagulation products in hemophilia /$rUri Martinowitz and Angelika Batorova -- $g9.$tInhibitors to factor VIII - immunology /$rJean-Marie R. Saint-Remy and Marc G. Jacquemin -- $g10.$tInhibitors to factor VIII - molecular basis /$rJohannes Oldenburg and Edward Tuddenham -- $g11.$tInhibitors to factor VIII - epidemiology and treatment /$rDonna DiMichele -- $g12.$tInhibitors to factor VIII - mild and moderate hemophilia /$rKathelijne Peerlinck and Marc G. Jacquemin -- $g13.$tInhibitors to factor VIII/IX : treatment of inhibitors - immune tolerance induction /$rCharles R. M. Hay -- $g14.$tInhibitors of factor VIII : treatment of acute bleeds /$rClaude Negrier -- $g15.$tAcquired inhibitors to factor VIII /$rCraig M. Kessler and Ekatherine Asatiani -- $g16.$tHemophilia B - molecular basis /$rPeter M. Green -- $g17.$tInhibitors in hemophilia B /$rIndira Warrier -- $g18.$tTreatment of inhibitors in hemophilia B /$rSimon A. Brown -- $g19.$tPharmacokinetics /$rSven Bjorkman and Erik E. Berntorp -- $g20.$tWork-up of a bleeding child /$rVictor S. Blanchette and Walter H. A. Kahr -- $g21.$tCare of the child with hemophilia /$rRolf Ljung -- $g22.$tThe neonate with hemophilia /$rAngela Thomas and Elizabeth Chalmers -- $g23.$tProducts used to treat hemophilia : evolution of treatment for hemophilia A and B /$rInge Scharrer and Thomas Becker -- $g24.$tProducts used to treat hemophilia : recombinant products /$rAkira Yoshioka -- $g25.$tProducts used to treat hemophilia : plasma-derived coagulation factor concentrates /$rPaul L. F. Giangrande -- $g26.$tProducts used to treat hemophilia : recombinant factor VIIa /$rUlla Hedner -- $g27.$tProducts used to treat hemophilia : dosing /$rMiguel A. Escobar -- $g28.$tProducts used to treat hemophilia : regulation /$rAlbert Farrugia -- $g29.$tJoint replacement /$rNicholas J. Goddard -- $g30.$tSynoviorthesis in hemophilia /$rE. Carlos Rodriguez-Merchan -- $g31.$tPseudotumors in patients with hemophilia /$rMichael Heim and Uri Martinowitz -- $g32.$tRadiology /$rHolger Pettersson -- $g33.$tMagnetic resonance imaging/joint outcome assessment /$rMarilyn J. Manco-Johnson and Ray F. Kilcoyne -- $g34.$tPhysiotherapy in the management of hemophilia /$rKaren Beeton and Jane Tuffley -- $g35.$tTransfusion transmitted disease : history of epidemics (focus on HIV) /$rW. Keith Hoots -- $g36.$tTransfusion transmitted disease : hepatitis C virus infection and liver transplantation /$rMargaret V. Ragni -- $g37.$tGene therapy : introduction and overview /$rGilbert C. White II and R. Jude Samulski -- $g38.$tGene therapy for hemophilia B /$rKatherine P. Ponder -- $g39.$tGene therapy for hemophilia A /$rGilbert C. White II and Paul E. Monahan -- $g40.$tGene therapy : molecular engineering of factor VIII and factor IX /$rDavid Lillicrap -- $g41.$tLaboratory assays in hemophilia /$rJorgen Ingerslev -- $g42.$tStandardization of assays /$rTrevor W. Barrowcliffe -- $g43.$tObstetrics and gynecology : hemophilia /$rRezan Kadir and Christine A. Lee -- $g44.$tvon Willebrand disease : molecular aspects /$rUlrich Budde and Reinhard Schneppenheim -- $g45.$tvon Willebrand disease : epidemiology /$rFrancesco Rodeghiero and Giancarlo Castaman -- $g46.$tvon Willebrand disease : biological diagnosis /$rEdith Fressinaud and Dominique Meyer -- $g47.$tClassification and clinical aspects of von Willebrand disease /$rAugusto B. Federici -- $g48.$tTreatment of von Willebrand disease : desmopressin /$rPier M. Mannucci -- $g49.$tTreatment of von Willebrand disease : therapeutic concentrates /$rPeter Collins -- $g50.$tWomen and von Willebrand disease /$rPeter A. Kouides -- $g51.$tFactor II /$rJan Astermark -- $g52.$tFactor V and combined factor V and VIII deficiencies /$rFlora Peyvandi and Marta Spreafico -- $g53.$tCongenital factor VII deficiency /$rGuglielmo Mariani and Alberto Dolce -- $g54.$tFactor X and factor X deficiency /$rDavid J. Perry -- $g55.$tFactor XI deficiency /$rUri Seligsohn -- $g56.$tFactor XIII /$rHans H. Brackmann and Vytautas Ivaskevicius -- $g57.$tFibrinogen /$rMichael Laffan -- $g58.$tMiscellaneous rare bleeding disorders /$rAmy Shapiro and Rekha Parameswaran -- $g59.$tQuality of life in hemophilia /$rSylvia v. Mackensen and Alessandro Gringeri -- $g60.$tThe economics of hemophilia treatments /$rAlec H. Miners -- $g61.$tComprehensive care and delivery of care : the developed world /$rChristopher A. Ludlam -- $g62.$tComprehensive care and delivery of care : the developing world /$rAlok Srivastava and Auro Viswabandya -- $g63.$tComprehensive care and delivery of care : the global perspective /$rBruce L. Evatt and Claudia Black.
520 1 $a"Covering how to asses both bleeding children and adults, Hemophilia A and B, molecular basis of the disease, the role of factors in coagulation, epidemiology, pharmacokinetics, and treatment of inhibitors. There is a section on musculoskeletal aspects of hemophilia as well as newer developments such as gene therapy and rare bleeding disorders."--BOOK JACKET.
650 0 $aHemophilia.$0http://id.loc.gov/authorities/subjects/sh85060214
650 12 $aHemophilia A$xphysiopathology.$0https://id.nlm.nih.gov/mesh/D006467Q000503
650 22 $aCoagulation Protein Disorders$xphysiopathology.$0https://id.nlm.nih.gov/mesh/D020147Q000503
650 22 $aFactor IX$xphysiology.$0https://id.nlm.nih.gov/mesh/D005164Q000502
650 22 $aFactor VIII$xphysiology.$0https://id.nlm.nih.gov/mesh/D005169Q000502
650 22 $aHemophilia B$xphysiopathology.$0https://id.nlm.nih.gov/mesh/D002836Q000503
700 1 $aLee, Christine A.$0http://id.loc.gov/authorities/names/n92804111
700 1 $aBerntorp, Erik.$0http://id.loc.gov/authorities/names/n2004123725
700 1 $aHoots, Keith.$0http://id.loc.gov/authorities/names/n93800324
856 41 $3Table of contents$uhttp://www.loc.gov/catdir/toc/ecip052/2004023743.html
852 00 $boff,hsl$hRC642$i.T46 2005 Q